IN8bio, Inc. (INAB) |
|
1.25 0.07 (5.93%)
|
03-22 12:20 |
|
Open: |
1.3066 |
Pre. Close: |
1.18 |
|
High:
|
1.3066 |
Low:
|
1.17 |
|
Volume:
|
33,459 |
Market Cap:
|
32(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 11:47:20 AM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 2.04 One year: 2.49 |
| Support: |
Support1: 1.12 Support2: 0.93 |
| Resistance: |
Resistance1: 1.75 Resistance2: 2.14 |
| Pivot: |
1.34  |
| Moving Average: |
MA(5): 1.2 MA(20): 1.39
MA(100): 1.9 MA(250): 2.23 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 13.5 %D(3): 11 |
| RSI: |
RSI(14): 32.8 |
| 52-week: |
High: 4.98 Low: 1.12 |
| Average Vol(K): |
3-Month: 91 (K) 10-Days: 83 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ INAB ] has closed above bottom band by 30.7%. Bollinger Bands are 35% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.25 - 1.26 |
1.26 - 1.26 |
|
Low:
|
1.15 - 1.16 |
1.16 - 1.17 |
|
Close:
|
1.17 - 1.18 |
1.18 - 1.19 |
|
Company Description |
|
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York. |
Headline News |
Wed, 22 Mar 2023
As IN8bio, Inc.'s market cap (NASDAQ:INAB) drops to US$29m, insiders might be questioning their decision to buy earlier this year - Simply Wall St
Mon, 20 Mar 2023
Bullish insiders bet US$1.8m on IN8bio, Inc. (NASDAQ:INAB) - Yahoo Eurosport UK
Thu, 16 Mar 2023
IN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform at AACR Annual Meeting 2023 - Yahoo Finance
Thu, 23 Feb 2023
Pre-Market Most Active for Feb 23, 2023 : LLAP, LCID, TQQQ, SQQQ ... - Nasdaq
Thu, 23 Feb 2023
IN8bio Shares Fall After Preclinical Data From Non-Signaling CAR ... - Yahoo Finance
Thu, 05 Jan 2023
IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
25 (M) |
| Shares Float |
10 (M) |
|
% Held by Insiders
|
25.7 (%) |
|
% Held by Institutions
|
9 (%) |
|
Shares Short
|
208 (K) |
|
Shares Short P.Month
|
106 (K) |
Stock Financials |
|
EPS
|
-1.21 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.21 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-38.9 |
|
Return on Equity (ttm)
|
-73.2 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.07 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-18 (M) |
|
Levered Free Cash Flow
|
-11 (M) |
Stock Valuations |
|
PE Ratio
|
-1.03 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.01 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.65 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
